UMDNJ/Rutgers University CounterACT Research Center of Excellence

UMDNJ/罗格斯大学 CounterACT 卓越研究中心

• 批准号: 7468064
• 负责人: JEFFREY D LASKIN
• 金额: $ 361.64万
• 依托单位: UNIV OF MED/DENT NJ-R W JOHNSON MED SCH
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-09-28 至 2011-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7468064
• 关键词: UMDNJ; Rutgers; University; CounterACT; Research

Sulfur mustard, a potent chemical warfare vesicant, is considered to be a high priority chemical threat. Although it has been studied for more than 80 years, the mechanisms mediating its actions as a vesicant remain unknown; moreover, to date, there are no effective medical countermeasures for exposure to warfare vesicants. The proposed UMDNJ/Rutgers University CounterACT Research Center of Excellence will specifically focus on the development of drugs to treat sulfur mustard poisoning. In collaborative studies with a local pharmaceutical company and Battelle Memorial Institute, we have identified two candidate classes of Pharmaceuticals that can prevent or reverse sulfur mustard toxicity. At least one member of each class of drugs has previously been approved by the FDA for other indications. In this academic/industrial partnership, plans are to optimize the lead compounds from the groups we have identified, to determine the active pharmacophores, and ultimately to synthesize structural isomers. We will also evaluate the efficacy of these potential countermeasures in model systems of sulfur mustard toxicity. In addition, Research and Development Projects are proposed that are designed to identify specific mechanisms of action of sulfur mustard and potential new targets for therapeutic intervention in three major vesicant targets: the eye, the skin and the lung. Investigators on these projects will work closely with a Pharmacology and Drug Development Core and a Medicinal Chemistry and Pharmaceutics Core with considerable expertise in drug development, providing insights to facilitate the development of sulfur mustard countermeasures. The research laboratories of the PI, co-Pi, Pi's of the Research and Development Projects, the Pharmaceutics group and Pharmacology and Drug Development Core are located in close proximity to one another on the Busch campus of Rutgers University. They are all members of the Environmental and Occupational Health Sciences Institute (EOHSI), a facility jointly sponsored by UMDNJ-Robert Wood Johnson Medical School and the School of Pharmacy at Rutgers University. EOHSI has been designated as an NIEHS Center of Excellence. The Medicinal Chemistry group is located at Lehigh University, approximately 25 miles from Rutgers University. The P.I. of this Center (J. Laskin) and the P.I. of the Medicinal Chemistry Core (N. Heindel) have been jointly funded by NIEHS on drug development grants for over 15 years. A Training and Education Program is proposed that will be directed at health care providers at Rutgers University School of Pharmacy, UMDNJ-School of Public Health, UMDNJ-Robert Wood Johnson Medical School and the Health Sciences Program at Lehigh University.

硫磺是一种有效的化学战泡沫，被认为是高优先级化学威胁。 尽管已经研究了80多年，但该机制介导了其作为囊泡的动作 仍然未知；此外，迄今为止，还没有有效的医疗对策来暴露于战争 囊泡。拟议的Umdnj/Rutgers大学抵抗卓越研究中心将 特别关注用于治疗硫芥末中毒的药物的开发。在与 当地的制药公司和巴特尔纪念研究所，我们确定了两个候选人类别 可以预防或逆转硫的芥末毒性的药物。每个班级的至少一个成员 药物以前已获得FDA批准其他适应症。在这个学术/工业中 合作伙伴关系，计划将优化我们确定的小组的铅化合物，以确定 活跃的药剂团，最终使结构异构体合成。我们还将评估 这些潜在的对策在硫芥末毒性的模型系统中。此外，研究和 提出了开发项目，旨在确定硫磺的特定作用机制 芥末和潜在的新靶标在三个主要囊泡靶标中进行治疗干预：眼睛， 皮肤和肺部。这些项目的调查人员将与药理学和药物紧密合作 开发核心以及具有大量药物专业知识的药物化学和药物核心 开发，提供见解，以促进硫芥末酱对策的发展。这 PI，Co-Pi，Pi的研究实验室研究与开发项目，药品 小组和药理学和药物开发核心彼此之间彼此之间相近 罗格斯大学的布希校园。他们都是环境和职业健康的成员 科学学院（EOHSI），由Umdnj-Robert Wood Johnson医学院共同赞助的设施 以及罗格斯大学的药学院。 Eohsi已被指定为Niehs中心 卓越。药物化学小组位于利哈伊大学，距离 罗格斯大学。 P.I.这个中心（J. Laskin）和P.I.药物化学核心（N。 Heindel）由NIEHS共同资助了15年以上的药物开发补助金。培训和 提出了教育计划，该计划将针对罗格斯大学学校的医疗保健提供者 药房，公共卫生的Umdnj-School，Umdnj-Robert Wood Johnson医学院和健康 利哈伊大学的科学课程。